Zenotech Laboratories

Zenotech Laboratories Net Debt per Share

The Net Debt per Share of Zenotech Laboratories (532039.BO) as of Oct 15, 2026 is -4.38 INR. In the previous year, Net Debt per Share was -3.23 INR — a change of 35.64% (lower).

Net Debt per Share

-4.38INR

YoY

35.64%

Last updated:

Net Debt per Share of Zenotech Laboratories is 2025 -4.38 INR. Net Debt per Share of Zenotech Laboratories was 2024 -3.23 INR. It decreases by 35.64% lower compared to the previous year.

The Zenotech Laboratories Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-4.65 INR
Jan 1, 2019
1.15 INR
Jan 1, 2020
2.88 INR
Jan 1, 2021
2.96 INR
Jan 1, 2022
0.56 INR
Jan 1, 2023
0.00 INR
Jan 1, 2024
-3.23 INR
Jan 1, 2025
-4.38 INR
The Zenotech Laboratories Net Debt per Share history
YEARNet Debt per ShareYoY
-4.38INR+35.64%
-3.23INR—
0.00INR-100.00%
0.56INR-81.02%
2.96INR+2.75%
2.88INR+149.50%
1.15INR-124.80%
-4.65INR-156.00%
8.31INR-0.47%
8.35INR-6.26%
8.91INR+15.65%
7.70INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd, listed on the Bombay Stock Exchange with ticker 532039.BO and ISIN INE486F01012, is a biotechnology company operating in the healthcare sector. Headquartered in Hyderabad, India, the company employs 150 full-time staff. Founded through an IPO on May 14, 1996, Zenotech focuses on the manufacturing and marketing of pharmaceutical products, specifically specializing in specialty generic injectables. Its production facilities are located in Turkapally village, Shamirpet Mandal, Telangana. The company's product portfolio includes oncology, biotechnology, and general injectables. Zenotech Laboratories Ltd maintains a website at http://zenotechlab.com/ for further information. The firm's operations are centered around the development and distribution of injectable pharmaceutical solutions, targeting both domestic and international markets. With its focus on injectables, the company aims to provide accessible and reliable healthcare products. The company's headquarters in Hyderabad serves as the central hub for its business activities, including research, development, and administrative functions. Zenotech's business model emphasizes the production of generic injectables, which are critical for various medical treatments, particularly in oncology and biotechnology sectors. The company's presence in the Telangana region, with its manufacturing facility in Turkapally, underscores its commitment to local manufacturing and supply chain efficiency. As a publicly traded entity, Zenotech Laboratories Ltd. provides investors with exposure to the biotechnology and pharmaceutical sectors within India's healthcare industry. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Net Debt per Share of Zenotech Laboratories is -4.38 INR in 2025.

Net Debt per Share of Zenotech Laboratories changed from -3.23 INR to -4.38 INR, representing a 35.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories